<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155814</url>
  </required_header>
  <id_info>
    <org_study_id>BXU537298</org_study_id>
    <secondary_id>QSC202208</secondary_id>
    <nct_id>NCT04155814</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects</brief_title>
  <official_title>Bioequivalence Study Assessing a Single Dose of Iron Sucrose Injection (Baxter) or a Single Dose of Venofer® Injection in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the bioequivalence, pharmacokinetic (PK) profile, and safety and&#xD;
      tolerability of Iron Sucrose (Test Product) relative to that of Venofer® in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">December 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax(delta)</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Maximum concentration (Cmax) across all time points for the delta difference between Total Iron (TI) and Transferrin Bound Iron (TBI). This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t(delta)</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Area under the concentration curve (AUC) from time zero to last time of quantifiable concentration (Tlast) for the delta difference in AUC0-t between TI and TBI. This is a PK test parameter to compare bioequivalence of two plasma drug products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Maximum concentration (Cmax) across all time points for both TI and TBI. This is a PK test parameter to compare bioequivalence of two plasma drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Area under the concentration-time curve (AUC) from time zero to last sample time for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Area under the concentration-time curve (AUC) from time zero extrapolated to infinity for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Time of occurrence of Cmax (Tmax) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Terminal phase half-life (t1/2) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Volume of distribution (Vz) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>Total body clearance (CL) for extravascular administration calculated by Dose/AUC for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUCex</measure>
    <time_frame>Hours before injection (24, 12, 0.25); Minutes after end of injection (1, 5, 10, 15, 30, 45); Hours after end of injection (1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36)</time_frame>
    <description>AUC0-inf due to extrapolation (AUCex) from Tlast to infinity calculated by: 100 × (AUC0-inf-AUC0-t)/AUC0-inf (%AUCex) for both TI and TBI. This is a PK test parameter to compare bioequivalence of two drug products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant laboratory abnormalities</measure>
    <time_frame>Day -28 (Screening) through Day 10 (Follow-up)</time_frame>
    <description>Any clinically significant abnormality will also be reported as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant findings on physical examinations</measure>
    <time_frame>Day -28 (Screening) through Day 10 (Follow-up)</time_frame>
    <description>Any clinically significant abnormality will also be reported as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes to ECG parameters</measure>
    <time_frame>Day -28 (Screening), Day -2, 0.25 hours before injection, and 6, 24 and 36 hours after end of injection</time_frame>
    <description>Any clinically significant abnormality will also be reported as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with occurrence of adverse events (AEs)</measure>
    <time_frame>Day -28 (Screening) through Day 30</time_frame>
    <description>An AE is any untoward medical occurrence in a subject that occurs either before dosing (referred to as a pre-dose AE) or once a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with occurrence of adverse events of special interest</measure>
    <time_frame>Day -28 (Screening) through Day 30</time_frame>
    <description>Special interest items includes hypersensitivity reactions including anaphylactic/anaphylactoid reactions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Bioequivalance</condition>
  <arm_group>
    <arm_group_label>Iron Sucrose Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venofer Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose Injection</intervention_name>
    <description>USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength</description>
    <arm_group_label>Iron Sucrose Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venofer Injection</intervention_name>
    <description>(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength</description>
    <arm_group_label>Venofer Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or non-pregnant, non-lactating healthy females&#xD;
&#xD;
          -  Age 18 to 55 years of age (both inclusive)&#xD;
&#xD;
          -  Must, in the opinion of the investigator, be in good health based upon medical&#xD;
             history, physical examination (including vital signs and ECGs) and clinical laboratory&#xD;
             tests assessed at the time of screening&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2 and a minimum body weight of 40 kg, or if&#xD;
             outside the range, considered not clinically significant by the investigator&#xD;
&#xD;
          -  Ferritin levels not less than the lower limit of normal as defined by clinical&#xD;
             laboratory reference ranges for female and male subjects at screening only&#xD;
&#xD;
          -  Transferrin Saturation (TSAT) not less than the lower limit of normal as defined by&#xD;
             clinical laboratory reference ranges for female and male subjects at screening only&#xD;
&#xD;
          -  Hemoglobin levels not less than the lower limit of normal as defined by clinical&#xD;
             laboratory reference ranges for male and female subjects&#xD;
&#xD;
          -  Must agree to use an adequate method of contraception:&#xD;
&#xD;
               -  For male subjects: Subjects willing to follow approved birth control methods (a&#xD;
                  double barrier method) for the duration of the study as judged by the&#xD;
                  investigator(s), such as condom with spermicide, condom with diaphragm, or&#xD;
                  abstinence. Subjects should also not donate sperm during this time.&#xD;
&#xD;
               -  For female subjects: Female subjects of childbearing potential, defined as a&#xD;
                  woman &lt; 55 years of age who has not had a partial or full hysterectomy or&#xD;
                  oophorectomy, must have a negative urine pregnancy test at screening and a&#xD;
                  negative beta human chorionic gonadotropin (β-hCG) pregnancy test at admission.&#xD;
                  Subjects of childbearing potential must use a medically acceptable means of&#xD;
                  contraception during their participation in the study&#xD;
&#xD;
          -  Non-smoker, defined as: Non-smoker for &gt; 12 months (i.e., subject has not smoked or&#xD;
             used any tobacco product, e-cigarettes, and nicotine replacement products for the 12&#xD;
             months prior to the start of the study) based on subject report.&#xD;
&#xD;
          -  Must be willing and able to comply with all study requirements&#xD;
&#xD;
          -  Must be able to understand a written informed consent, which must be obtained prior to&#xD;
             initiation of study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to iron sucrose or iron products&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients&#xD;
&#xD;
          -  Clinically significant abnormal biochemistry, hematology or urinalysis as judged by&#xD;
             the investigator&#xD;
&#xD;
          -  History of iron deficiency within 6 months prior to screening&#xD;
&#xD;
          -  History of anemia within 6 months prior to screening&#xD;
&#xD;
          -  Suspicion of iron overload as evidenced by both elevated serum TSAT and serum ferritin&#xD;
             levels&#xD;
&#xD;
          -  History of hemochromatosis&#xD;
&#xD;
          -  Bleeding disorders, acute bleeding or recently documented hemorrhage&#xD;
&#xD;
          -  Females with history of hypermenorrhea or menorrhagia&#xD;
&#xD;
          -  History of cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine,&#xD;
             immunological, dermatological, neurological or psychiatric disease or disorder, as&#xD;
             judged by the investigator&#xD;
&#xD;
          -  Must not have significant serious skin disease, including rash, food allergy, eczema,&#xD;
             psoriasis, or urticaria&#xD;
&#xD;
          -  Female subjects who are currently pregnant, lactating, or planning to become pregnant&#xD;
             during the study period&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  Positive drugs of abuse test result or history of drug abuse in the past 6 months&#xD;
             based on subject report&#xD;
&#xD;
          -  Positive urinalysis test for alcohol at screening or history of alcoholism in the past&#xD;
             6 months based on subject report&#xD;
&#xD;
          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week&#xD;
             (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of&#xD;
             wine, depending on type)&#xD;
&#xD;
          -  Administration of an injectable drug within 14 days prior to drug administration in&#xD;
             this study&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other&#xD;
             than up to 4 g per day acetaminophen in the 14 days before IMP administration,&#xD;
             hormonal contraceptives, or hormone replacement therapy. Exceptions may apply on a&#xD;
             case by case basis, if considered not to interfere with the objectives of the study,&#xD;
             as agreed by the PI and sponsor's medical monitor&#xD;
&#xD;
          -  Use of iron supplements (including iron-containing multivitamins) within 3 months of&#xD;
             the first dose IMP administration in the study&#xD;
&#xD;
          -  Have poor venous access that limits phlebotomy&#xD;
&#xD;
          -  Subjects who have donated blood (1 unit = 450 mL) within 3 months prior to the first&#xD;
             dose of the study drug and plasma within 7 days prior to the first dose of the study&#xD;
             drug.&#xD;
&#xD;
          -  Subjects who have received any IMP in a clinical research study within 5 half-lives or&#xD;
             within 30 days prior to first dose. However, in no event, shall the time between last&#xD;
             receipt of IMP and first dose be less than 30 days&#xD;
&#xD;
          -  Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          -  Subjects who have previously been enrolled in this study&#xD;
&#xD;
          -  Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baxter Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

